Neogenomics, Inc.
NEO
$10.10
-$0.44-4.18%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 2.49% | 2.02% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 2.49% | 2.02% | |||
| Cost of Revenue | 1.94% | 1.02% | |||
| Gross Profit | 3.17% | 3.29% | |||
| SG&A Expenses | 4.82% | -4.39% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 3.30% | -1.62% | |||
| Operating Income | -12.94% | 30.99% | |||
| Income Before Tax | 9.64% | 6.14% | |||
| Income Tax Expenses | -436.00% | 60.00% | |||
| Earnings from Continuing Operations | 13.42% | 5.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 13.42% | 5.06% | |||
| EBIT | -12.94% | 30.99% | |||
| EBITDA | -41.41% | 270.74% | |||
| EPS Basic | 13.56% | 5.49% | |||
| Normalized Basic EPS | -26.89% | 38.89% | |||
| EPS Diluted | 13.93% | 6.67% | |||
| Normalized Diluted EPS | -26.89% | 38.89% | |||
| Average Basic Shares Outstanding | 0.16% | 0.43% | |||
| Average Diluted Shares Outstanding | 0.16% | 0.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
